Mutated KRas is seen in greater than 90% of pancreatic cancer cases, and it allows cancer cells to behave more like a stem cell. This study aims to target the stem cell markers expressed on KRas expressing pancreatic cancer cells in hopes of sensitizing them to chemotherapy and more effectively killing them.